In comedy, the more you can surprise the audience by subverting their expectations, the better. There is nothing better than coming up with a brilliant set piece, something that writers and actors can ...

In medieval Denmark, people could pay for more prestigious graves closer to the church — a sign of wealth and status. But when researchers examined hundreds of skeletons, they discovered something ...

There are two kinds of Monty Python fans: casual rewatchers and the devotees who can quote every sketch from memory. If you're the latter, "Spamalot" is for you. Why it matters: The musical adapts ...

Beckoning audiences on a whimsical jaunt to always look on the bright side of life, the touring revival of “Spamalot” is especially winning for its unabashed determination to deliver on all manners of ...

Jeremy has more than 2300 published articles on Collider to his name, and has been writing for the site since February 2022. He's an omnivore when it comes to his movie-watching diet, so will gladly ...

Taglines: And now! At Last! Another film completely different from some of the other films which aren't quite the same as this one is.

Scientists may have spotted a long-sought triplet superconductor — a material that can transmit both electricity and electron spin with zero resistance. That ability could dramatically stabilize ...

CNBC's Jim Cramer explains why he is keeping an eye on shares of Grail and Coreweave. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to ...

Shares of early cancer-detection test maker Grail plunged 50% early Friday after a landmark U.K. study showed the test didn’t significantly reduce later-stage cancer cases. Grail said late Thursday ...

Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His ...

The trial was designed to demonstrate a statistically significant reduction in Stage III and Stage IV disease, but the primary endpoint wasn't met. It's possible that the follow-up data will prove ...